00:49 , Aug 17, 2019 |  BioCentury  |  Emerging Company Profile

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...
23:20 , Aug 15, 2019 |  BC Innovations  |  Distillery Techniques

Targeting a KRAS allosteric site with designed ankryin repeat proteins (DARPins)

TECHNIQUES CATEGORY: Chemistry TECHNOLOGY: Tool compound An AstraZeneca plc and University of Oxford team identified two DARPins that act as allosteric inhibitors of KRAS and could expand treatment of KRAS mutant cancers beyond those with...
22:07 , Aug 14, 2019 |  BC Extra  |  Clinical News

Aug. 14 Clinical Quick Takes: Lynparza boosts ovarian cancer survival in first-line setting; plus Novavax, Gritstone and Solid

Lynparza extends PFS in first-line ovarian cancer  Lynparza olaparib plus bevacizumab as first-line maintenance therapy met the primary endpoint of significantly extending progression-free survival (PFS) vs. standard-of-care bevacizumab alone in advanced ovarian cancer patients in...
23:03 , Aug 9, 2019 |  BC Extra  |  Company News

Allakos sustains its gains on strength of GI readout

Not even the dilution of an upsized follow-on offering could slow Allakos' momentum as its share price marched north steadily through midweek on the strength of Phase II data in eosinophilic gastrointestinal disorders, suggesting investors...
18:56 , Aug 9, 2019 |  BC Extra  |  Clinical News

AZ notches another win in cancer with Tagrisso in NSCLC

AstraZeneca continued its momentum of positive cancer news this summer as Tagrisso osimertinib showed a survival benefit in first-line NSCLC. AstraZeneca plc (LSE:AZN; NYSE:AZN) said the oral irreversible inhibitor of EGFR activating mutations significantly improved...
23:52 , Aug 8, 2019 |  BC Innovations  |  Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
01:02 , Aug 8, 2019 |  BC Extra  |  Company News

Aug. 7 Company Quick Takes: Panel backs narrower PrEP label for Descovy; plus Teva, Blueprint, DBV and more

FDA panel backs narrower PrEP label for Descovy FDA’s Antimicrobial Drugs Advisory Committee voted 16 to 2 that Gilead Sciences Inc. (NASDAQ:GILD) has provided sufficient evidence that Descovy emtricitabine/tenofovir alafenamide is safe and effective for...
23:32 , Aug 7, 2019 |  BC Extra  |  Clinical News

Aug. 7 Clinical Quick Takes: Waylivra cuts triglycerides in Phase III; plus Lynparza, Moderna, Athenex and Opthea

Waylivra hits Phase II/III endpoint in FPL  Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said Waylivra volanesorsen cut serum triglyceride levels by 88% vs. 22% for placebo (p<0.001) in patients with familial partial...
20:08 , Aug 5, 2019 |  BC Extra  |  Clinical News

Big gain for Allakos as first-in-class GI program heads toward pivotal phase

Allakos' management team has plenty of experience in M&A, and a new Phase II readout in eosinophilic GI disorders could provoke interest in the company as a Phase III-ready bolt-on acquisition target. Allakos Inc. (NASDAQ:ALLK)...
23:33 , Aug 2, 2019 |  BC Extra  |  Clinical News

SillaJen, Transgene fall with latest oncolytic virus setback

The failure of Pexa-Vec from Transgene and SillaJen in a Phase III study is the latest blow to the oncolytic virus field, but it may say less about the modality as a whole than about...